Vangipuram R, Tyring S K
School of Medicine, Department of Dermatology, The University of Texas Medical Branch, Galveston, TX, USA
Department of Dermatology, University of Texas Health Sciences Center, Houston, TX, USA.
Skin Therapy Lett. 2017 Nov;22(6):1-4.
Atopic dermatitis (AD) is the most common chronic inflammatory disease affecting 2-10% of adults and up to 15-30% of children. Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option. In clinical trials, it has demonstrated efficacy by reducing clinical activity and symptoms, and showed improvement in the AD genomic phenotype, including a significant reduction in Th2 chemokines and reversal of key epidermal markers of AD. It also has a favorable safety profile. This review discusses the role of dupilumab in treating Th2 related inflammation, and its efficacy and safety, as demonstrated in clinical trials. Dupilumab (Dupixent®) recently gained US FDA approval for patients with moderate-to-severe AD, and is poised to revolutionize the management of this chronic, relapsing condition.
特应性皮炎（AD）是最常见的慢性炎症性疾病，影响2%至10%的成年人，以及高达15%至30%的儿童。尽管患病率不断上升，但由于毒性和副作用，针对中重度AD患者的有效且安全的治疗方法仍然有限。度普利尤单抗是一种白细胞介素（IL）-4和IL-13拮抗剂，可限制2型辅助性T细胞（Th2）驱动的炎症活动，是一种很有前景的治疗选择。在临床试验中，它通过降低临床活动和症状证明了疗效，并显示出AD基因组表型有所改善，包括Th2趋化因子显著减少以及AD关键表皮标志物的逆转。它还具有良好的安全性。本综述讨论了度普利尤单抗在治疗Th2相关炎症中的作用，以及其在临床试验中所证明的疗效和安全性。度普利尤单抗（Dupixent®）最近获得了美国食品药品监督管理局（FDA）对中重度AD患者的批准，并有望彻底改变这种慢性复发性疾病的管理方式。
